Alicia Roston, MD
Urology · Wailuku, HINPI 1700380029
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Axonics, Inc. at 42.7% of the total. Reporting peaked in 2024 at $2,702 and has fallen 72.2% since, to $750 in 2025.
Across 81 payments — averaging $51.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Astellas Pharma US Inc$503
- Pfizer$337
- Johnson & Johnson$320
- Boston Scientific$256
- AbbVie$161
- plus $798 from 11 others
What the payments were for
- Travel & lodging$1,49536%
- Food & beverage$2,29755%
- Education$3559%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 12 | $1,771 |
| Astellas Pharma US Inc | 14 | $503 |
| Pfizer | 10 | $337 |
| Johnson & Johnson | 6 | $320 |
| Boston Scientific | 6 | $256 |
| AbbVie | 8 | $161 |
| Teleflex LLC | 8 | $156 |
| Travere Therapeutics, Inc. | 1 | $150 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Bayer | 3 | $72 |
| Seagen Inc. | 1 | $55 |
| Endo USA, Inc. | 2 | $47 |
| Urogen Pharma, Inc. | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Merck | 2 | $41 |
| 180 Medical, Inc. | 2 | $36 |
| Medtronic | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,147 in reported general payments places this provider in the 70th percentile of 46 urology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 108 | $114,287 |
| GemtesaVibegron | 13 | $18,577 |
| Estradiol | 91 | $6,015 |
| Tamsulosin Hcl | 233 | $3,401 |
| Solifenacin Succinate | 72 | $2,747 |
| Finasteride | 147 | $2,261 |
| Tolterodine Tartrate | 12 | $1,529 |
| Testosterone | 11 | $1,426 |
| Desmopressin Acetate | 13 | $1,227 |
| Cephalexin | 36 | $672 |
| Ciprofloxacin Hcl | 82 | $306 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $283 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 55 | $266 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $239 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 56 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $503 | $114,287108 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $125 | $18,57713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 46 urology providers in Hawaii.
Other urology in Wailuku
- Soren CarlsenWailuku$6K
- Todd HoekstraWailuku$0
- Benjamin ShurtleffWailuku$0
- Sergei TikhonenkovHonolulu$22K
- Timur RoytmanHonolulu$22K
- Franklin LeeAiea$12K
- Robert CarlileHonolulu$10K
- Charles KimHonolulu$9K
- David WeiHonolulu$9K
- Andrew SunHonolulu$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.